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Abstract: Infertility has recently been construed to be a serious problem in sub-Saharan 
Africa. This problem seems to be viewed as of low priority with reference to the effective 
and efficient allocation of available health resources by national governments as well as by 
international donors sponsoring either research or service delivery in the public health sector. 
In this paper the problem of infertility in Nigeria is surveyed with a view to assessing the ethical 
dimension of proposals to manage infertility as a public sector priority in health care delivery. 
The   population/individual and public/private distinction in the formulation of health policy 
has ethical implications that cannot simply be ignored and are therefore engaged in critically 
assessing the problem of infertility. Cost–utility analysis (such as Quality Adjusted Life-Year 
composite index) in the management of infertility in Nigeria entails the need for caution relevant 
to the country’s efforts to achieve Millennium Development Goals. This should remain the case 
whether the ethical evaluation appeals to utilitarian or contractarian (Rawlsian) principles. The 
“worst off” category of Nigerians includes (1) underweight children less than 5 years of age, 
with special concern for infants (0–1 years of age) and (2) the proportion of the population 
below a minimum level of dietary consumption. The Rawlsian ethic implies that any Federal 
Ministry of Health policy aimed at establishing public programs for infertility management 
can be considered a “fair” allocation and expenditure if, and only if, the situation for these two 
cohorts is not thereby made worse. Nigerian health policy cannot assume this type of increased 
allocation of its resources to infertility care without it being hard pressed to warrant defensible 
moral or rational argument.
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Introduction
A recent issue of Nature described the problem of infertility in sub-Saharan Africa 
to be “rampant on the continent.”1 For the purpose of this discussion, we shall adopt 
as a definition of infertility that set forth in the guidelines of the Royal College of 
Obstetricians and Gynaecologists (UK): “failure to conceive after regular sexual 
intercourse for two years in the absence of known reproductive pathology.”2 This 
definition excludes both moderate and severe subfertility couples, given that, (1) “71% 
of moderately and 21% of severely sub-fertile couples conceive spontaneously within 
2 years,” (2) “95% of moderately and 45% of severely sub-fertile couples conceive 
within 5 years,” (3) “few treatment interventions have been proven to be effective 
in improving impaired chances of conception in cases of subfertility,” and it is 
important also to exclude adolescent subfertility given the ongoing development of 
the reproductive function of this age cohort.3International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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The very idea of rampant infertility in sub-Saharan Africa 
may be unfamiliar to foreigners, as they are accustomed to 
reports of ubiquitous poverty and high rates of morbidity 
and mortality from infectious and parasitic disease. They are 
also alerted to a growing prevalence of chronic   degenerative 
diseases, all compounded by severe malnutrition and basic 
impediments due to inferior environmental quality. That 
infertility can be construed an “urgent” problem in sub-
Saharan Africa seems quite beside the point of effective and 
efficient allocation of available health resources by national 
governments as well as by international donors   sponsoring 
either research or service delivery in the public health   sector. 
Recommendations for adjustment to national health policies 
seem all the more out of place relative to recently adopted 
population-planning policies and the actual cost of infertility 
treatment facilities. Van Zandvoort reports that to   establish 
an assisted reproduction technique (ART) unit according to 
international standards costs US$400,000 to US$500,000.3 
In this paper, the problem of infertility as found in Nigeria 
is discussed, with view to assessing the ethical dimensions 
of proposals to manage infertility as a public sector priority 
in health care delivery.
Infertility in Nigeria
Fertility rates in Nigeria have been put at approximately 
six children per woman4 notwithstanding a “high rate of 
pregnancy wastage.”5 The World Health Organization World 
Health Report6 shows a value of 6.5 children per woman 
for 1994 and 5.7 for 2004. These data seem at odds with 
growing concerns about infertility as such. As Hollos7 put it, 
“The problem of infertility in sub-Saharan Africa (including 
Nigeria) received comparatively little attention until recently.” 
Hollos further emphasized that the problem of infertility 
“was obscured by the region’s high fertility rates, which gave 
rise to a global climate of concern over population growth 
and high fertility that is not conducive to the perception of 
infertility as a real problem.”
However, Okonofua reports that, of 780 couples visiting 
the reproductive health clinic of the Women’s Health and 
Action Research Centre in Nigeria in 2002, more than half 
were found to have severe causes of infertility.8 Araoye 
reported that the major cause of infertility in Nigeria is 
infection: sexually transmitted diseases (STDs) and post-
arbortal and puerperal sepsis, with the problem by no means 
restricted to women.9 However, male infertility is regarded as 
taboo, a problem that no one will admit exists.10 This taboo 
itself is a contributor to practices of polygyny, with women 
all too frequently assumed by the local population to be the 
primary culprit of infertile marriages, and male infertility is 
handled with discretion to protect male dignity.4 Previous 
studies in Nigeria have focused on the possible contributions 
of environmental factors, such as diets and toxic elements,11–13 
sociocultural behaviors and sociodemographic factors,14,15 
infection,16,17 and hormones.18,19
Studies seeking to characterize the genetic background of 
infertility in Nigeria have indicated that about 39.5% of the 
normozoospermic population has reduced CAG repeats and a 
lower percentage of the infertile population (23%) has shown 
moderately increased repeats.20 Such studies may have   serious 
implications for making decisions on   treatment strategy, 
especially hormonal replacement therapy in hypogonadism. 
Patients affected by some forms of genetic alterations 
  produce a higher frequency of sperm with aneuploidies; 
hence, an increased risk of congenital abnormality in the fetus 
exists as produced by in vivo   fertilization or intracytoplasmic 
sperm injection (IVF/ICSI).21 Moreover, genetic conditions 
may also be transmitted to the offspring, thereby creating 
transgenerational infertility or other health problems.
Setting aside statistical data to glance at the individual 
faces of infertility, one frequently finds women (rather than 
men) whose personal stories are cause for indignation and 
ethical concern, as the news feature in Nature10 makes starkly 
clear: several years ago, Betty Chishava was thrown out of her 
family home in Harare, Zimbabwe, because she had failed 
to fall pregnant and did not want to sleep with her husband’s 
brother. Desperate for an heir and a cure for the stigma of 
infertility, her husband Herbert took a new wife. Betty was 
left penniless and alone. A similar picture is painted in an 
article published in Population and Developmental Review22: 
Kaddy Sisay, a 30-year-old remarried divorcee had carried 
at least four pregnancies. Three were with her first husband. 
The firstborn, a daughter who died before age 3 years, was 
followed by two stillbirths. At this point Kaddy’s marriage 
ended, very likely as a consequence of her failure to produce 
children for her husband. Remarrying as the marginal second 
wife of a man already married to a younger woman with 
three children, Kaddy became pregnant for the fourth time 
and bore another son when she was about 21 years of age. 
This child died and Kaddy was left in a precarious marriage 
with no children to support her in later life.
Consider next the example of Jeannette,7 who, at 31 years 
of age, manifested secondary infertility after the birth of a 
male child and suffering four miscarriages. Her concern was 
that when she gets old there will be nobody to help her. She 
did not believe that her husband’s children (from other wives) 
would help her. She also knew that when her husband died International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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she would have to go back to her home community, since 
she would have no right to remain in his compound. His son 
(from another wife) would come back and force her out of 
her matrimonial home.
The foregoing examples disclose how infertile women 
become marginalized and are forced to find “coping 
mechanisms” as they move from initially monogamous 
  marriages to situations of polygyny with a corresponding 
change in rank order of wives relative to manifest fertility. 
The lack of proper management of male infertility also 
means that women are forced to be more persistent about 
seeking treatment, adding unnecessarily to the burden upon 
reproductive health service resources, limited as they are 
in developing countries.3 For women facing traditional 
perspectives on life, infertility becomes a radical “life-
altering problem.” The fact is that infertility carries with it 
significant psychological trauma, such that it is meaningful 
to speak of “health-related quality of life” concerns for 
infertile women.23,24 Data from studies continue to show 
that 5/10 girls and 7/10 boys have had sexual intercourse at 
least once by the time they leave secondary school.25 Further, 
extramarital infidelity among men is more tolerated than 
among women, especially where infertility contributes to 
the practice of polygyny. Hence, local custom and cultural 
determinants of belief and behavior are wholly central to 
a meaningful understanding of the problem, even as those 
involved in infertility treatment by way of advanced methods 
of reproductive technology work to propose “methods for 
developing simpler, low-cost alternatives to the high-tech 
drugs and equipment currently used for fertility treatments.”10 
At the same time, health promotion and education on sexual 
practices are equally (if not more) important given the pri-
mary cause of infertility in preventable STD infection.
Without doubt, there are questions of resource allocation 
here that involve the more general ethical question of 
achieving distributive justice within the public health 
and private medical care sectors. Nigeria, for example, 
experienced its first successful use of IVF in 1989, yet 
Giwa-Osagie remarked recently that, despite that success, the 
nation’s budget priority in health care continued to be given 
to the high visibility diseases such as malaria and diarrhea.10 
This remark manifests an assumption that biomedical research 
and consequent successful employment of biomedical 
technologies entail more large-scale commitment of the 
public’s resources. This as an expression of a permissible, 
if not mandatory, shift in priorities. Yet, as van Balen and 
Gerrits26 remarked, “emphasizing the need to formulate a 
policy on ‘how to deal with infertility’, does not necessarily 
imply that new reproductive technologies (NRTs) should 
be introduced and financed by the public health system.” 
In published work, Okonofua has “cautioned that such an 
approach would be inappropriate as the new reproductive 
technologies are not likely to be cost-effective in resolving 
infertility in Africa, and could reduce available funds needed 
to address other escalating health problems.”27 In the case of 
Nigeria, the nation’s attention to high-visibility diseases and 
thereby to vulnerable population groups is commendable 
and considered a right response to fulfillment of Millennium 
Development Goals (MDGs). However, the African response 
to MDGs, 5 years into her implementation, is particularly 
slow, especialy throughout sub-Saharan Africa. Giwa-
Osagie’s remark also does not account for the distinction 
between the goals of medicine and those of public health, 
within the national context of policy formulation.10 This by no 
means diminishes the value of Giwa-Osagie’s perspective.10 
However, his perspective does not adequately account for the 
ways in which private medical care is delivered in Nigeria. 
Alubo28 acknowledges that “irrespective of source, health 
care development in Nigeria is largely limited to curative 
services, with prevention, promotion, rehabilitation and 
other aspects receiving attention only on paper.” But, Alubo 
has argued effectively that there are important “limitations 
of private medicine in addressing the prevailing burden of 
disease and death in Nigeria,” including the fact that the 
“for-profit motive and high fees also limit access to private 
medical enterprise (PME) services”: “The fee regime means 
that most people cannot afford the services in a country of 
high and rising poverty and unemployment. In effect, only 
clients covered by some third party arrangements such as 
retainership can afford PME services.”28 Thus, it will often 
be the case that the goals of medicine as expressed by 
physicians practicing in the private sector will necessarily 
(thus, with defensible ethical warrant) be subordinated to 
those of public health, given the country’s pattern of disease 
and the resources available in the public sector and under the 
purview of a ministry of public health. This is all the more so 
in a case such as Nigeria, which has a national health system 
per capita expenditure of US$9.44.29 Infertility as a problem 
faces stiff competition for available resources in this context. 
Given that “current health spending in most low-income 
countries is insufficient for the achievement of the health 
MDGs,” it is debatable that infertility reasonably has a place 
in public sector financing, though it has a place in privately 
financed options via established fertility clinics in Nigeria. 
Clinics in Lagos and Port Harcourt have “state-of-the-art 
laboratories,” performing “more than 500 cycles of IVF International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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treatment a year.”10 The contrast is patently clear relative to 
public and private resource availability: “In Nigeria a single 
IVF treatment costs around US$2500. But the minimum 
wage in Nigeria is just US$52–US$60 a month and there 
are a great many people scraping by on a dollar a day, or 
less,”10 with “those lucky enough to have jobs” receiving “on 
average the equivalent of US$30 a month.”28 Thus, it comes 
as a surprise to many involved in global health policies that 
researchers “are lobbying hard to put African infertility on 
the international agenda.”9 Research in progress for lower-
cost alternatives to state-of-the-art IVF is yet to move beyond 
the laboratory to clinical trials. Hence, the ethics of ART 
use in sub-Saharan Africa are yet to be properly engaged 
as proposals move forward for public sector responses to 
infertility, even in Nigeria.
WHO and those working to implement and attain the 
MDGs make it clear that, “Progress will equally depend on 
getting policies right, making the institutions that implement 
them function effectively, building health systems that work 
well and treat people fairly and ensuring there are enough staff 
in post to do all the work.”30 In the case of Nigeria this would 
include an increase in per capita expenditure within the health 
system from US$9.44 to US$34 as recommended by the 
WHO. Of course, as former WHO Director-General, Dr Lee 
Jong-wook, conceded, “The MDGs do not say everything 
that needs to be said about health and development” – and he 
specifically mentioned reproductive health as one of the needs 
not included in the MDGs.30 Nonetheless, to characterize the 
MDGs as “the most important outcomes that development 
should achieve” is to prescribe the basic focus of concerted 
collaborative action from national governments, international 
governmental and non-governmental organizations, and 
donors. Given the sociocultural context of Nigerian infertility, 
however, it would seem that any arguments favoring public 
sector allocations would have to relate to either the MDG 
of “gender equality” or “maternal health” or both. But, this 
argument is for the moment lacking.
Issues of cost-effectiveness
It has been said, quite correctly, that, “Every [medical] 
practitioner is motivated to maximize outcome.”31 This 
is so even for the infertility specialist and is consistent 
with traditional practitioner obligations such as nonma-
leficence and beneficence. The problem here, however, is 
to specify the outcome in the management of infertility, 
beginning with diagnostics, exploring relevant treatments 
short of ART, and then committing to one or another ART 
intervention in the given case, but with attention paid to 
reasonable cost-  effectiveness.32 Developing countries such 
as Nigeria, on the verge of public policy commitments to 
infertility care stand to learn from mistaken approaches 
to the management of infertility in developed nations, 
especially on the question of outcomes assessment, even 
as they may find reason for   caution in structuring national 
policy, given available cost data, eg, for IVF, which varies 
significantly by age (eg, in Thailand the cost for IVF delivery 
for women ,38 years = £9,747 [US$15,500] while that for 
women .38 years is £38,946 [US$62,500]).33
Moreover, it has been argued31 that, “most infertility 
  treatments have entered the clinical mainstream without 
prior outcome assessment.” If the practitioner’s comportment 
is one of maximizing outcome, it is important that a ministry 
of health in a developing country like Nigeria be clear about 
what outcomes it seeks in the management of infertility such 
that it can pursue allocative decision-making responsibly. 
Surely in Nigeria the expected and/or authorized outcome 
cannot be that of maximizing conception rates because, as 
Gleicher31 points out, such an outcome measure will simply 
lead to “indiscriminate” practices (eg, multiple implantations) 
that result in “higher multiple conception rates,” which 
implies “higher clinical risks” and thus “also higher obstetric 
and neonatal costs” due to “an increase in prematurity and 
severe prematurity.” The cost implications can be staggering: 
“The neonatal intensive care costs [assuming these services 
would even be available in a developing country such as 
Nigeria as part of a reproductive health policy, planning, and 
programming scheme] of a single very premature infant can 
exceed the total infertility costs of hundreds of couples.”31 
This does not include maternity post-partum care, which 
adds further to the cost factor. These are not costs that 
public sector financing can accommodate   readily as the 
outcome of infertility   treatment is engaged by the   available 
obstetric/gynecological services as well as specialized 
(neonate)   pediatric services. Where there are   public–private 
  partnerships encouraged by a ministry of health in such 
a   setting, therefore, there cannot be overemphasis on an 
  important criterion: “The fertility specialist carries a   principle 
[sic] responsibility for obstetric outcome.” The policy impli-
cation here is that, “the final cost of infertility treatment 
  cannot be assessed until maternal and neonatal outcomes 
are assessed”31(italics added).
The important question, then, is: what is the appropriate 
outcome expected in the management of infertility if 
  cost-effectiveness analysis is to benefit decision-making 
and actual health status?31 Gleicher answers appropriately: 
“The appropriate outcome end-point for infertility treatment International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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is birth and/or discharge of the mother and neonate after 
birth rather than conception” (italics added). This outcome 
thereby accounts for negative externalities associated with 
pregnancy following ART, given that though conception may 
occur, there are significant complications that may ensue for 
both mother and fetus. Thereby, quality of life post-partum 
for both the (previously) infertile couple and neonate takes 
center stage.
QALY as a component of ethical review
A composite indicator of health status such as QALY   (quality 
adjusted life-year) may be appropriate as a measure to inform 
the allocative decision at policy level. It is a utilitarian 
method that seeks an objective estimate of consequences,34 
thus a form of cost–utility analysis35 setting forth “the ratio 
of the incremental cost to incremental effectiveness,” the 
general objective being that of determining “the optimal set 
of health-care interventions that will maximize societal well 
being.”36 It is a measure of health in a population designed to 
  “estimate the quantitative health benefits from intervention,”37 
specifically “differences in health benefits at the margin,” 
(italics added)38 thus, it is a concern for marginal utility.
QALY also counts as a “summary indicator for burden 
of disease assessment,” and is specifically designed “to 
provide a guiding principle for selecting among tertiary 
health care interventions.”36 Thus, alternative interventions 
are “ranked” in terms of “cost per QALY,” with the allocative 
decision made in preference of those interventions having 
the lower cost comparatively. The focus on comparison 
thereby distinguishes cost-effectiveness analysis of QALY 
from a cost-minimization analysis, where both costs and 
consequences are considered in the special case where 
outcomes are shown to be equivalent.39 The cost–utility 
element of the QALY means that, “the opportunity cost 
of scarce health care resources is defined in terms only of 
QALYs foregone.”40 This can be done without reference 
to a budget constraint (“no explicit limit on health-care 
expenditures”), or it can be a calculation undertaken with 
reference to an operating budget limit (“maximize QALYs 
while holding costs within the given health-care budget”) 
(Donaldson and Bate;41 as cited by Bala et al36). Some health 
economists recommend using “a specified price per QALY 
gained rather than a fixed budget as the decision rule,” the 
reason being that, “it is possible to include all the costs in 
the analysis, instead of only the costs that fall in the specific 
budget.”42 Whatever the decision rule chosen, one of the 
attractive features of the QALY as a composite measure is 
its incorporation of identifiable/identified “preferences for 
various health outcomes.”43 Despite such calculations and 
accounting for preferences the problem still remains from 
where one is to receive the budget resources and where 
the utility analysis permits implementation of a program.44 
Generally, “the rule” in cost-effectiveness analysis is that 
“the required budget for a new cost-effective therapy has to 
be taken from the existing less cost-effective treatments in 
the health care sector.”44 Of course, this is not to say there are 
no other disadvantages to using a composite measure such as 
QALY. As Doctor et al45 noted, “A disadvantage of the QALY 
model is that it represents individual preferences for health 
only under restrictive assumptions”; and “Empirical tests 
of the QALY assumptions have generally yielded negative 
results.” The problem is to know how to measure “expected 
utility” adequately when comparing alternative health care 
interventions. One of the difficulties is determining “data 
for quality,” given that “its perception is so personal and 
variable,” even as perceptions of health status will vary 
with comorbidities (eg, sequelae such as the neurological 
status of stroke, compounding a primary morbidity such 
as hypertension), in which case an adequate measure of 
effectiveness would account for both “the target condition” 
and “the companion condition.”46 Since it is a utilitarian 
measure relating cost to effectiveness, a given use of QALY 
may not allocate to “the worst off” in a given setting of 
health care, the argument being that, “the net benefit of the 
treatment [eg, if the elderly and disabled were considered to 
be the worst off cohort] would be lower than the net benefit of 
treatments for younger and generally healthier people.”47
This is important in the case of cost–utility analysis in the 
management of infertility in Nigeria, especially given that 
the developing country context with its socioeconomic and 
  cultural variables is rather different from that of an industri-
alized nation. The question remains, importantly, what the 
QALY composite measure happens to be in a given assess-
ment; the fact is that “the patient in front of us may choose 
differently,” hence, one cannot ignore both the ambiguity and 
the diversity involved in rational choice available to those who 
can and should be involved in policy decisions. Lehmann46 
provides a useful reminder of recommendations made by 
the US Public Health Service Panel on Cost-Effectiveness in 
Health and Medicine (1996) that remain relevant to a QALY 
assessment, eg, (1) “all health effects should be included in 
the effectiveness measure”; (2) “cost-effectiveness should 
be evaluated with respect to status quo treatment”; (3) 
  “community preferences should be used”; (4) “the analysis 
should make a place for adjustment due to age, gender, and 
race.” Further, as Glannon and Moss47 observed, allocation International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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to the worst off is not inconsistent with a QALY-based jus-
tification. They explain the importance of emphasizing that 
the “priority to the worst off is a conditional rather than an 
absolute principle.” In their opinion, this “depends not only 
on how much they will benefit (which is what QALYs mea-
sure), but also on whether the use of resources for them will 
limit the use of resources for others who could be raised to 
the decent minimum.” The utilitarian standard, of course, 
remains central: “The crucial point is to use resources so that 
the greatest number will be raised to, or remain at, a decent 
minimum of normal functioning.”47
Generally speaking, nonetheless, the calculations for 
QALY include the following components38: (1) Cost-
  Effectiveness Ratio = cost of services/(health gain ×   duration), 
(2) Cost of Services = charges for treatment, including all 
services and drugs, (3) Quality of Well-Being = sum of 
“severity weight” (W), each W state the probability that 
QWB state would occur, (4) Health Gain = QWB with 
  treatment – QWB without treatment. It has been noted48 
that, “The point of an allocation scheme such as the QALY 
is that it is to be objective by being independent of the pref-
erences and   prejudices of the allocator.” This comportment 
is   consistent with the utilitarian desideratum of impartiality 
and benevolence in the decision.
Thus, “A system of resource allocation based on QALYs 
may actually aid a more equitable distribution of health 
care, since QALYs (if properly elicited) are valued the same 
no matter whom they accrue to.”38 QALY, of course, will 
involve subjective assessments of quality of well-being, even 
if there are sample surveys designed specifically to collect 
psychometric data from patients and practitioners involved in 
the treatment of given medical conditions. It is now more or 
less accepted practice that studies include sensitivity analyses 
to assess the impact of uncertainty surrounding health-state 
values on final estimated cost effectiveness ratios.44 This will 
be the case also for assessments of alternative approaches 
to infertility in a developing country such as Nigeria. Those 
involved in ART biomedical research more often than not 
are clinical researchers concerned with the application of 
ART relative to observed or projected “direct clinical effect” 
rather than being concerned with quality of life assessments 
per se. Thus, various ART option are stated in terms of 
“average cumulative pregnancy rate.”49 Yet, it is the quality 
of life assessment that provides meaningful decision-making 
evidence where health policy analysis is designed to assist 
in resolving resource allocation dilemmas.
Quality of life assessment in the case of Nigerian men and 
women suffering from infertility will include both a disability 
score (DS), representing physical impairment in reproductive/
procreative function [0 = no disability; 1 = equivalent to 
death], as well as a social distress   modifier (SDM) across 
several rating levels [A. None; B. Mild; C. Moderate; and 
D. Severe]. As noted earlier, the WHO Global Burden of 
Disease Report assigned infertility to disability level 3 out of 
7 categories, for a “severity weight” (“how incapacitated the 
person is as a result of the disease”) of 0.12–0.24 (ie, 12% 
to 24% incapacity of normal function). A further operative 
assumption in the QALY scheme is that immediate benefits 
from a particular health care intervention are more valuable 
than future benefits, hence the need for discounting (eg, 
use of a 5% discount rate over a selected period of time, 
eg, 15 years.50 Discounting is particularly important in 
  comparing interventions associated with treatment in contrast 
to those aimed at prevention. The fact is that, “ ‘Identified’ 
lives saved by treatment in the present hold more influence 
than ‘statistical’ lives saved in the future by an equivalent 
investment in prevention,” as Phillips and Holtgrave32 have 
observed. Accordingly, they point out that since the benefits 
of prevention occur mainly in the future, while the costs of 
prevention occur primarily now, the process of discounting 
then affects the cost-effectiveness of prevention. They also 
report that since “the benefits of treatment occur more often 
in the present … discounting tends to have less impact on 
its calculated cost-effectiveness.”  There is also the factor of 
preference associated with income status: “individuals with 
lower incomes often value future benefits less than those with 
higher incomes,”32 hence the importance of using a standard 
“social discount” rate.51
Consistent with the foregoing, then, quality of life 
assessment will also have to consider the comparative value of 
(A) alternative treatments for the affected sub-group of the 
population suffering infertility and (B)   strategies of prevention 
(health education/health promotion) for the sub-group of the 
population at risk of infertility but not yet in a position to 
require treatment as such. (A) can include medical treatment 
for primary STI such as gonorrhea and   Chlamydia trachomatis 
as well as specific infertility treatments (eg, gonadotrophin 
drugs), surgical treatment (eg, surgical   correction of epididy-
mal blockage, tubal microsurgery), and assisted reproduction 
(eg, IVF, ICSI, artificial insemination by donor), thus medi-
cal management of both male- and female-factor fertility 
  problems. (B) would include the panoply of interventions 
aimed at prevention of STDs in both men and women whose 
infertility is etiologically linked to STDs deriving from unsafe 
sexual practices and sequelae of STI, hence the importance 
of risk-reduction investigation (including contact tracing) International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
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and treatment. Because of logistical difficulties associ-
ated with contact   tracing in a developing nation   context of 
programming, it may be that risk-reduction would be initi-
ated through screening for   incidence/prevalence rather than 
tracing contacts as such. The point to bear in mind here is 
that whatever the policy choice between (A) and (B), or, 
more likely, a choice of some mix of (A) and (B), the fact 
is that “many interventions can have an impact on quality 
of life and that these need not be medically necessary or 
essential interventions” – the implication of which is that, 
“we need to have non-arbitrary criteria [sic] for ruling in 
particular interventions for consideration.”56 However, there 
is a further point at issue here: “we need to have rules about 
whose quality of life is to be counted and how it is to be 
estimated.”48 Here justice in resource allocation (distributive 
justice) elicits the ever-present question of entitlement: Who 
is entitled to what services within the available resource 
constraints and restraints on performance? This is important 
in the case of programming in reproductive health care given 
that the annual cost per participant will vary across public 
health and clinical interventions. For example, WHO bank 
data for 1993 estimated cost per participant in low-income 
countries: health education (including family planning, 
nutrition information) about US$2.4 per   participant; AIDS 
prevention about US$112 per participant; prenatal and 
delivery care about US$90 per participant; family planning 
about US$12 per participant; treatment of STDs about US$11 
per participant.52 These cost estimates do not include costs 
associated with infertility treatment. Ikechebelu49 reports a 
cost of N400,000 (US$2565) for IVF treatment in Nigeria 
and considers the preference for diversion of funds to primary 
health care both “parochial and prejudicial” (though with the 
concession that ART is to be considered a legitimate choice 
“for those who can afford it and desire to have a child of 
their own”).
The ethical dilemma and alternative 
theoretical dispositions
Health policy scholar Larry Churchill29 commented, “ethical 
problem solving without the benefit of theoretical reflection 
is like digging a garden with one’s bare hands rather than 
using the appropriate tools,” even as one may reasonably 
say, in balance, “theoretical reflection that is untested by 
involvement in the concrete particulars of life is like reading 
about gardens without ever planting and tending one.” The 
foregoing question – “Who is entitled to what services 
within the available resource constraints and restraints 
on performance?” – attests to the problem of identifying 
standards of assessment. This is a problem of ethics, given 
asserted claims of entitlement to specified services.
The question is: if an infertile couple in the UK (or 
similar industrialized nation) can lodge an entitlement claim 
to infertility care merely on the basis of a general right to 
health care under purview of the National Health Service, 
may an infertile couple in Nigeria (or similar developing 
country) do likewise, and do so insisting that there should 
be no “double standard” in the administration of a “fair” 
health care opportunity from its own Federal Ministry 
of Health? In other words, if some service/intervention 
is considered to be medically sound or valid in the UK, 
ceteris paribus, is that service/intervention reasonably to 
be affirmed to be acceptable in Nigeria? Arguments may be 
provided either way, without ready resolution of the point 
at issue. McMillan,53 for example, has argued in favor of 
construing infertility treatment as a medical need given its 
associated disruption of normal (reproductive) function and, 
thus, a limitation of fair equality of opportunity (pregnancy, 
being a parent, raising a family, and so on) that resource 
allocation decisions should therefore address. Medical need 
would then be one plausible reason to support a national 
policy to manage infertility. The problem here, however, is 
that any application of a concept of medical need is faced 
with charges of “ambiguity, indeterminacy, subjectivity 
[and] value-ladenness,”54 hence recommendations by some 
health economists to engage preferences rather than needs. 
Infertility care would then be more reasonably construed to 
be a preference of varying intensity for those seeking such 
care alternative to a focus on preferences is to engage “basic 
needs” defined as “needs requisite for sustaining life,” and 
such needs are “considered to be directly related to required 
courses of action without which a patient ceases to be 
functional.”54 The question here is whether the argument can 
be made defensibly that the management of infertility in a 
setting such as Nigeria is regarded as a response to a basic 
need. That is an unlikely argument, in which case Cohen’s 
caution that it is important if one is to use QALY as a measure: 
“the issue of what QALY analysis measures, in particular 
what the quality of life adjustment factor measures, is one 
that should be examined before one can constructively discuss 
distributional principles.54 Yet, the fact is that decision-
making in the health sector is unavoidably faced with real 
resource constraints and uncertainty in projected outcomes, 
whatever one’s commitment theoretically or ideologically 
as a matter of political economy or moral philosophy.55 The 
resource constraints for Nigeria are no less real and palpable 
for both the public sector under the purview of the Federal International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Ministry of Health as well as for the private sector, the latter 
responding as best it can to be consistent with private fertility 
clinics and fee-for-service pay schemes (that are more often 
than not “out-of-pocket” as they enjoy private insurance or 
retainerships).
Even a resource-capable country such as the UK with 
its National Health Service (NHS) cannot implement such 
a policy without accounting for a shift in demand for ser-
vices. For example, in setting forth guidelines for the clinical 
management of infertility, the National Institute for   Clinical 
Excellence (NICE) provides costing information along with 
clinical guidelines.56 Implementing the new clinical guide-
lines entails significant cost considerations: (1) 70% of cur-
rent privately treated patients could demand NHS treatment, 
thus expanding the public cost burden; (2) the cost of substitu-
tion (private demand becoming NHS demand) would be about 
£33.3 million with the cost of growth being £50.6 million, 
for a total cost impact of £83.9 million; (3) there would be 
an additional ongoing increase in the level of IVF services 
demand over time; (4) an 80% increase in IVF provision 
would entail 66% more babies born, 27% of these babies 
being premature births requiring neonatal intensive care, so 
that the NHS would experience an increase of £4.1 million in 
neonatal intensive care costs; (5) total cost impact of imple-
menting the clinical guidelines (after accounting for some 
savings elements) is £81 million. The foregoing cost data are 
instructive in pointing to the fact that the mere formulation 
of a policy and setting forth implementation (clinical) guide-
lines entails a serious cost impact. This is no less the case in 
a developing country and, thus, for any advocacy on behalf 
of an infertility policy to be implemented by the Nigerian 
Federal Ministry of Health. In fact, the cost implications are 
even more severe in the case of a developing country such as 
Nigeria where pregnant women do not enjoy optimal nutrition 
but experience deficiencies that lead to anemia and exposure 
to risk of infection.57
So, the ethical question remains: how is one to respond to 
the assorted infertility care interests expressed here insofar 
as these interests have a bearing upon the formulation of a 
national health policy in Nigeria? Let us consider this   question 
in terms of the debate within an ethical theory between those 
who advocate a utilitarian approach to the allocative decision 
and those who advocate a justice as fairness (“contractarian”) 
approach – the ethical decision then being gauged in terms of 
a commitment to either a principle of utility (or principle of 
“average” utility, as argued by Harsanyi58) or the difference 
principle (as articulated by John Rawls). Here it is instructive 
to consider the arguments presented for the Rawlsian 
approach to ethics and health policy, presented by Danis 
and Sepinwall29 and then assess that position in relation 
to the criticisms of Rawls’s theory as presented by Harsanyi.58 
Presumably, arguments in favor of “justice as fairness” as 
applied to health sector decision-making generally could 
be articulated more specifically relative to the problem of 
infertility in a developing country setting of decision, even 
as the utilitarian argument can be likewise developed for the 
purpose of comparative instruction.
Danis and Sepinwall assert, reasonably enough, that we 
can adduce plausible hypotheses about pathways that link 
social inequalities to health, that justice requires that we ask 
whether social determinants of health are fairly distributed 
and that where they are not fairly distributed we are to take 
steps to address the sources of health inequality. Danis and 
Sepinwall29   consider a series of evidence claims about social 
determinants of health, making it clear on empirical grounds 
that income/health gradients (eg, life expectancy in relation 
to gross domestic product per capita) are not the result of 
some fixed or determinate laws of economic development 
but instead are influenced by policy choices. Further, they 
argue, income/health gradients are not merely the result of 
deprivation of the poorest groups but operate across the 
whole socioeconomic spectrum within societies – and this 
would hold true for a developing economy as well. There are 
identifiable social and psychosocial pathways through which 
inequality produces its effects on health status (eg, income 
inequality leads to educational inequality which leads to 
health inequality). These causal pathways are amenable to 
specific policy choices that can and should be guided by con-
siderations of justice. Hence, it is important that we consider 
what theoretical approach to justice is sufficiently defensible 
for the purpose of making health policy choices.
The question at issue here is how those suffering the 
problem of infertility are to be evaluated with respect to 
their interest in fertility care, but relative to the criterion 
stipulated by the difference principle. According to the 
Rawlsian scheme, every policy, thus including any proposed 
policy to manage infertility, is to be evaluated by accounting 
for the impact that implementation of the policy would 
have on “those worst off” within the given society (impact 
positive and/or negative, including externalities). Hence, the 
empirical question is unavoidable: “Who, among Nigerians 
in this case, count as the ‘worst off,’ and according to what 
measure(s)?”
Before engaging this question, however, let us contra-
pose to the Rawlsian approach the utilitarian theoretical 
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and   Sepinwall29 distinguished between what they called 
  “identified victims” (“those who are ill and who have known 
needs”) and “statistical victims” (“those whose lives would 
be spared illness by robust public health measures and a fair 
distribution of social determinants” of health). As they rightly 
say, utilitarians “would then push us immediately to   maximize 
net benefit by allocating resources from saving identified 
victims to saving statistical ones.” They would do so only 
on the basis of a commitment to impartiality in decision and 
allocation. Harsanyi58 identifies this as an “equiprobability 
assumption,” ie, “an expression of the purely moral principle 
that, in making basic moral value judgments, we must give 
the same a priori weight to the interests of all members of 
the society.” If here the identified victims are (for purposes 
of the present argument) the set of men and women who have 
been identified as infertile couples, then the estimated benefits 
and costs may very well mean that “the greatest good” (ie, 
health status by a set of measures of mortality/morbidity/com-
posite rates) for “the greatest number” of Nigerians entails 
a significant restriction on allocation of available public 
resources to the identified infertile couples and preference in 
allocation (because of the cost-effectiveness or cost-benefit 
ratio) for the public at large (statistical victims) who stand 
to benefit from prevention measures. The utilitarian seeks 
to maximize expected utility (net benefit) from alternative 
policy/program options, such that the cost-effectiveness or 
cost-benefit calculation may very well entail the commitment 
of disposable resources to the statistical victims rather than 
to the identified victims.
The contrast between the Rawlsian and utilitarian 
approaches is evident. In both cases identified victims 
(infertile couples) will surely have their personal preferences, 
expressed as a pressing need and demand for treatment of 
their infertility with the intended medical outcome being a live 
birth without maternal complications or infant prematurity 
and need for intensive neonatal care not to mention the social 
and psychological outcomes. In the utilitarian approach it is 
expected that one can assume the position of the identified 
victims yet suspend judgment of the value of their particular 
interests, then view the prospective allocation options 
impartially, without granting priority to anyone whatever their 
current health status, socioeconomic status, and so on. That 
is, while taking the utilitarian approach even the identified 
couples would manifest “a serious attempt. But when taking 
the Rawlsian approach, the identified couples would expect 
their own needs/interests in infertility care to be satisfied if, 
and only if, those worst off among the Nigerian populace 
are not thereby made worse off, in accordance with the 
difference principle. Thus, infertile couples individually and 
as an aggregate would defer to the needs/interests/preferences 
of those worst off and weight this group’s needs/interests/
preferences in health care accordingly.
Let us consider the central question presented by the 
Rawlsian approach: “Who, among Nigerians in this case, 
are considered to be the ‘worst off,’ and according to what 
measure(s)?” The answer to this question can be given 
defensibly in empirical evidence associated with MDGs 
(to which the Government of Nigeria is committed as a 
  matter of policy); and here “the worst off” is referred to as 
(1) underweight children less than 5 years of age, with special 
concern for infants (0–1 years of age), thus attention to the 
0- to 5-year-old age cohort in the interest of reducing infant 
and child mortality and morbidity; and (2) the   proportion 
of population below minimum level of dietary energy 
  consumption. This means, under the Rawlsian ethic, that 
any Federal Ministry of Health policy aimed at establishing 
public programs for infertility management can be considered 
a “fair” prospective allocation and expenditure if, and only 
if (1) and (2) cohorts are not made worse off thereby. A fair 
determination of this datum requires that we consider the 
projected cost-effectiveness or cost/benefit ratio associated 
with infertility management of the “identified victims” (thus, 
prevalence/incidence data) and outline the opportunity costs 
(ie, the benefits foregone from not allocating those resources 
to [1] and [2] program options).
For the purposes of this analysis (to illustrate the point), 
we may use the survey value of 17% infertility for the 20- 
to 44-year-old cohort in Nigeria.59 Whatever the policy, 
there is an unavoidable budget constraint on decision 
making. The operating assumption of available resources 
of the Nigerian health system is the WHO-recommended 
(optimistic)   figure of US$34 per capita expenditure, while 
recognizing, of course, that it is more probable the per capita 
expenditure for health care will barely approach US$15 in 
the years remaining to achieve the MDG objectives up and 
through 2015. Since those “worst off” among Nigerians 
include children 0–5 years of age, data from the WHO 
World Health Report for 20066 are relevant: For the year 
2004, WHO estimates child mortality (CMR) in Nigeria to 
be 198 per 1000 (uncertainty in putting the range anywhere 
between 174/1000 and 220/1000). The age cohort ,5 years 
of age for 2005 is estimated at 21.3 million more or less 
evenly distributed male/female, with growth in this cohort 
projected to be at 31.7 million by 2025. With a CMR of 
198/1000 this means about 4.2 million Nigerian children 
0–5 years of age die annually. The World Bank reports child International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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malnutrition (as % of children ,5 years of age) to be 29%, 
roughly 6.2   million children, with the Food and Agricultural 
Organization (FAO) reporting 38.3% of child malnutrition 
characterized as stunting and 9.3% as wasting. FAO also 
reports 9% of Nigerians as being undernourished for the 
period 2001–2003 (11.5 million Nigerians), dietary energy 
consumption in Nigeria for the same period being 2700 kcal/
person/day. The foregoing data are to compare with the 
20- to 44-year-old cohort estimated to be at 42.7 million, 
17% (7.2 million) of these estimated to suffer (disability/
incapacity) from (mostly secondary) infertility.
Conclusion
When considering the Rawlsian approach, the difference prin-
ciple would have us consider whether we can fairly intervene 
(ie, distribute available resources) on behalf of 7.2 million 
infertile individuals by whatever treatment regime (1) without 
making 21.3 million unhealthy children worse off, especially 
the 4.2 to 6.2 million children whose pattern of infection and 
disease entails severe malnutrition and/or mortality, and, at 
the same time, (2) without making 11.5   million undernour-
ished Nigerians worse off as they suffer from inadequate 
dietary energy consumption.
The realities of a total budget available for the public 
health care sector, and the high rates of child morbidity and 
mortality related to the population cohorts as identified above, 
are starkly clear. Equally clear is the political mandate of the 
national/federal authority to respond to a significant public 
health responsibility, given significantly reduced purchasing 
power among Nigerians for private medical care. In this con-
text of ministry operations, the Nigerian health policy cannot 
assume the sort of increased allocation of  its resources to 
infertility care (making use of ART), as advocates prefer 
and now recommend, without finding itself hard pressed, 
to provide a defensible moral warrant for such a policy and 
associated programming. Hence, infertility treatment may 
morally and logically be a low priority for a public funding 
in Nigeria on macroethical grounds, and is better left to 
the private sector. A national policy that will empower and 
create a more productive operating environment for private 
sectors may be more beneficial. Also from a public health 
perspective, public sector priority in health care delivery 
prevention of infertility as one strategy to reduce the number 
of couples suffering from infertility should be vigorously 
pursued. It is obvious that from the data available for realistic 
QALY analysis and related specifically to applied Rawlsian 
criteria, there is a high probability that the opportunity costs 
to the worst off Nigerians would be austere once resources 
are allocated to infertility care. This would then make it a 
  morally indefensible policy.
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